Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

748.48 -1.44 (-0.19%)
Streaming Delayed Price Updated: 1:52 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
99 100 Next >
7 A-Rated Stocks for Your June Buy List
While there's no bad time to buy A-rated stocks, these equities represent companies that are must-own picks for June 2024. 
Via InvestorPlace
3 Valuable Stocks That Are Worth the Expensive Price Tag
Putting your hard-earned money into the stock market? Here are expensive stocks worth buying for the long-term. 
Via InvestorPlace
Ben & Jerry's Co-Founders Not Worried About Ozempic's Impact On Ice Cream Business: Here's Why
Ben Cohen and Jerry Greenfield, the co-founders of Ben & Jerry's, are not worried about the impact of weight-loss drugs on their ice cream business, despite the impending spin-off of their parent... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Active Fund Managers Bet These 6 Stocks Will Trade Near All-Time Highs
Active fund managers making large bets on momentum plays indicate confidence that Big Tech's rally has legs for the remainder of 2024. 
Via Benzinga
Chart Of The Day: Eli Lilly - More New Highs
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. 
Via Talk Markets
This Is What Whales Are Betting On Eli Lilly and Co
Via Benzinga
The Next 7 Trillion-Dollar Stocks to Buy: June 2024 Edition
The next trillion dollar stocks have emerged in a few key areas that investors should understand in greater detail in order to profit. 
Via InvestorPlace
Better Growth Stock: Archer Aviation or Viking Therapeutics?
Which one of these potential disruptors is the better buy? 
Via The Motley Fool
2 Reasons Why Eli Lilly's Stock Likely Hasn't Peaked
The stock may seem expensive right now, but that may not be the case in a few years. 
Via The Motley Fool
Alphabet Among Stocks Hitting All-Time High Tuesday: See Which Stocks Just Came On IBD's Top Stock Screens
Google-parent Alphabet hit a fresh high at 184.03 Tuesday. Its earnings rose the past year to a 53% surge to $1.74 per share last quarter. 
Via Investor's Business Daily
Novo Nordisk's Older Generation Weight-Loss Drug Saxenda Associated With Decreased Bone Mass Density, Study Shows
Novo Nordisk's Saxenda study published in JAMA Network Open reveals significant declines in bone density among patients, raising concerns for similar weight loss drugs. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
What's Going On With Eli Lilly Stock On Tuesday?
Eli Lilly collaborates with Microsoft-backed OpenAI to leverage generative AI for developing novel antimicrobials targeting drug-resistant pathogens. This partnership supports Lilly's commitment to... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
NVO Stock: Novo Nordisk Pops as China Approves Wegovy Weight Loss Drug
Novo Nordisk and Eli Lilly dominate the market for GLP-1 drugs, and are racing ahead to produce more of them. 
Via InvestorPlace
1 Supercharged Vanguard Index Fund to Buy Before It Soars 174%, According to a Wall Street Analyst
The Vanguard S&P 500 ETF includes many of the most influential stocks in the world, such as Microsoft, Apple, Nvidia, Alphabet, and Amazon. 
Via The Motley Fool
Topics ETFs Stocks
Exposures US Equities
What's Going On With Eli Lilly Shares Monday?
Eli Lilly and Co (NYSE: LLY) shares are moving higher Monday following the release of positive Phase 3 trial results for its weight loss drug, tirzepatide, marketed as Zepbound. 
Via Benzinga
Why ResMed Shares Are Trading Lower Monday
ResMed stock is trading lower Monday after Eli Lilly and Company released data from a clinical trial in regards to the treatment of sleep apnea. 
Via Benzinga
Will Novo Nordisk Building Fires Serve As A Catalyst For Eli Lilly? Redditors See A Stock Split For US Company 'Very Likely'
Eli Lilly's stock may rise due to supply issues at competitor Novo Nordisk, according to Reddit users. Its weight loss drug and upcoming FDA approval are also factors. Investors are optimistic about... 
Via Benzinga
Exposures Product Safety
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
The Top 3 Sectors Poised For Growth This Summer
Communications, technology, and healthcare are the three hottest sectors for growth, but not all stocks will rise with the tides. 
Via MarketBeat
Topics ETFs
ALT Stock Alert: Altimmune Pops on Weight-Loss Drug Findings
Altimmune (ALT) stock is soaring and trending after the company reported data on its GLP-1 weight-loss drug today. 
Via InvestorPlace
Eli Lilly's Weight-Loss Drug Takes Down ResMed, Inspire Medical — Again
Eli Lilly tested its weight-loss drug in people with obesity suffering from sleep apnea events. 
Via Investor's Business Daily
Eli Lilly's Zepbound For Weight Loss Shows Disease Resolution In Obese Sleep Apnea Patients, Lays Further Groundwork For Label Expansion
Eli Lilly's phase 3 SURMOUNT-OSA trials show tirzepatide injection significantly reduces apnea events in adults with obesity and moderate-to-severe obstructive sleep apnea. FDA decision expected by end... 
Via Benzinga
Exposures Product Safety
AbbVie Inc. Dividend Stock Analysis - Saturday, June 22
Here are some highlights from a detailed, quantitative analysis AbbVie Inc. stock. Let's take a closer look at various factors, such as the stock's value and dividend. 
Via Talk Markets
MarketBeat Week in Review – 6/17 - 6/21
Markets were calmer this week, with the Dow index posting the biggest gains, but it's too early to tell if this is the start of a broader market rally 
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
3 Biotech Stocks to Buy Now: June 2024
These are the three best biotech stocks to buy for long-term returns and portfolio stability due to their target patient populations, 
Via InvestorPlace
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments. 
Via Benzinga
Lawsuit Could Challenge Trust In Ozempic And Other Popular Weight Loss Drugs
Weight loss drug manufacturers Novo Nordisk and Eli Lilly are being challenged in court. The companies are accused of failing to properly warn patients about associated risks. 
Via Talk Markets
Topics Lawsuit
Exposures Financial Legal
Pre-Market Movers - June 21, 2024
Sarepta jumps after announcing expanded approval of DMD drug and more news on today's top movers. 
Via Talk Markets
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.